Teva Pharmaceutical Industries (TEVA) Tax Provisions (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Tax Provisions for 18 consecutive years, with $121.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Tax Provisions rose 255.13% year-over-year to $121.0 million; the trailing twelve-month figure through Jun 2026 stood at $12.0 million (down 87.1% YoY), and the FY2025 full-year result was -$180.0 million, down 126.63% from the prior year.
• Tax Provisions grew to $121.0 million in Q2 2026 per TEVA's latest filing, from $67.0 million in the prior quarter.
• Across five years, Tax Provisions topped out at $630.0 million in Q2 2024 and bottomed at -$900.0 million in Q2 2022.
• Historically, Tax Provisions has averaged $1.9 million across 5 years, with a median of $34.5 million in 2023.
• The sharpest annual moves came in 2024 and 2025: Tax Provisions jumped 4037.5% in 2024, then slumped 1492.86% in 2025.
• Over 5 years, Tax Provisions stood at $149.0 million in 2022, then sank by 72.48% to $41.0 million in 2023, then sank by 31.71% to $28.0 million in 2024, then plunged by 1492.86% to -$390.0 million in 2025, then jumped by 131.03% to $121.0 million in 2026.
• According to Business Quant data, Tax Provisions over the past three periods registered $121.0 million, $67.0 million, and -$390.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.